No, do not give acetaminophen (Tylenol) to a patient with hemiplegic migraine in the absence of headache.
Acetaminophen is indicated for the treatment of headache pain, not for isolated aura symptoms or motor weakness without accompanying headache. The medication works as an analgesic and has no established mechanism or evidence for treating neurological aura symptoms like hemiparesis when they occur independently.
Rationale Based on Evidence
Indication-Specific Treatment
The most recent guidelines 1 and FDA labeling 2 clearly indicate that acetaminophen is used for "temporary relief of occasional headaches and minor aches and pains." All treatment algorithms focus on pain relief as the primary outcome measure, with endpoints including "pain freedom at 2 hours" and "pain relief at 2 hours."
Hemiplegic Migraine Considerations
In hemiplegic migraine specifically, expert consensus 3 states that "acetaminophen and NSAIDs often are the first choice in acute treatment"—referring to treatment of the headache phase. The literature distinguishes between:
- Headache treatment: Where acetaminophen has established efficacy
- Aura symptom treatment: Where "an effective treatment for the severe and often prolonged aura symptoms is more warranted, but currently no such acute treatment is available" 3
Clinical Algorithm for Hemiplegic Migraine
When headache is present:
- Start with acetaminophen (1000 mg) or NSAIDs for mild-moderate pain 1, 3
- Escalate to triptans if inadequate response (though controversial in hemiplegic migraine due to theoretical vascular concerns) 3
When only motor aura/weakness is present without headache:
- Acetaminophen provides no benefit for isolated motor symptoms
- Focus on supportive care and monitoring
- Consider preventive therapy if attacks are frequent (>2 per month) 3
Important Caveats
Medication Overuse Risk
Using acetaminophen without appropriate indication (i.e., in absence of pain) contributes to medication overuse headache risk, defined as ≥15 days per month of NSAID/acetaminophen use 1. This can paradoxically worsen the overall migraine burden.
Emerging Preventive Options
For patients with frequent hemiplegic migraine attacks, newer CGRP monoclonal antibodies show promise for reducing both headache days and days with weakness 4, making prevention rather than inappropriate acute treatment the better strategy.
Cost and Resource Considerations
The 2025 ACP guidelines 1 emphasize prescribing medications only when clinically indicated and cost-effective. Using acetaminophen without headache wastes resources and exposes patients to unnecessary medication without benefit.
The key principle: Treat what is present. Acetaminophen treats pain, not neurological deficits. If the patient has isolated motor symptoms without headache, observation and preventive strategies are more appropriate than administering an analgesic that cannot address the underlying pathophysiology of cortical spreading depression causing the aura.